What's Happening?
Labcorp has launched the first FDA-cleared rapid fentanyl test manufactured in the United States, designed to deliver results in just 10 minutes. This test, known as the Labcorp Fentanyl Urine Visual Test, is intended for use in emergency departments,
hospitals, and clinics to quickly identify fentanyl exposure. The test detects norfentanyl, the primary metabolite of fentanyl, which remains in urine for up to 48 hours after exposure, providing a longer detection window than fentanyl itself. The test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics, and is cleared for use by qualified professionals in Clinical Laboratory Improvement Amendments (CLIA)-certified settings. Labcorp emphasizes the importance of rapid and reliable screening tools in emergency care, especially as synthetic opioids like fentanyl become more prevalent.
Why It's Important?
The introduction of this rapid fentanyl test is significant in addressing the growing concern of fentanyl exposure in clinical settings. With synthetic opioids becoming increasingly prevalent, healthcare providers require quick and dependable tools to inform patient care. The ability to rapidly detect fentanyl exposure can lead to faster and more effective treatment, potentially improving patient outcomes in emergency situations. This development aligns with recent guidance from the Association for Diagnostics and Laboratory Medicine, which underscores the need for reliable screening tools in emergency care. By providing actionable results in minutes, the test supports healthcare teams in making informed decisions, ultimately enhancing patient safety and care quality.
What's Next?
Labcorp plans to transition product names, packaging, and resources from MEDTOX Diagnostics to Labcorp Point of Care throughout 2026. As the test becomes more widely available, it is expected to be integrated into standard practices in emergency departments and clinics across the country. Healthcare providers may begin to rely more heavily on rapid testing methods to manage opioid-related cases, potentially influencing protocols and treatment strategies. The broader adoption of such tests could also prompt further innovations in rapid diagnostic tools, enhancing the overall capability of healthcare systems to respond to drug-related emergencies.
